Jazz Pharmaceuticals' Suvecaltamide (JZP385) Did Not Achieve Statistical Significance At 30Mg Versus Placebo On Primary Endpoint Of Change From Baseline To Week 12 On Essential Tremor Rating Assessment Scale Modified Composite Outcome Score
Portfolio Pulse from Benzinga Newsdesk
Jazz Pharmaceuticals' Suvecaltamide (JZP385) did not achieve statistical significance at 30mg versus placebo on the primary endpoint of change from baseline to week 12 on the Essential Tremor Rating Assessment Scale Modified Composite Outcome Score. The trial also did not meet the key secondary endpoint of the Clinical Global Impression-severity Scale.
June 20, 2024 | 11:56 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Jazz Pharmaceuticals' Suvecaltamide (JZP385) failed to meet both primary and key secondary endpoints in its trial for essential tremor, which could negatively impact investor sentiment and the stock price in the short term.
The failure to meet both primary and key secondary endpoints in a clinical trial is a significant setback for any pharmaceutical company. This news is likely to negatively impact investor sentiment and the stock price of Jazz Pharmaceuticals in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100